Knuth A, Wölfel T, Meyer zum Büschenfelde K H
Klinikum, Johannes-Gutenberg-Universität, Mainz, Germany.
Curr Opin Immunol. 1991 Oct;3(5):659-64. doi: 10.1016/0952-7915(91)90093-g.
The key issue in tumor immunology is to identify antigens as target structures for a cancer-selective immunological attack in the tumor-bearing host, resulting in tumor rejection. There is a growing detailed understanding of structural and regulatory gene alterations giving rise to candidate rejection antigens and peptides in tumor cells. As well as reviewing the development of new adjuvant and recombinant vector systems, new approaches are suggested for the construction of cancer vaccines.
肿瘤免疫学的关键问题是识别抗原，将其作为在荷瘤宿主中进行癌症选择性免疫攻击的靶结构，从而导致肿瘤排斥。人们对导致肿瘤细胞中候选排斥抗原和肽的结构和调控基因改变有了越来越深入的了解。除了回顾新型佐剂和重组载体系统的发展，还提出了构建癌症疫苗的新方法。
